CDT Equity Inc. (NASDAQ:CDT – Get Free Report) was the recipient of a large decrease in short interest in August. As of August 14th, there was short interest totaling 9,954 shares, a decrease of 45.3% from the July 30th total of 18,200 shares. Approximately 1.4% of the company’s stock are sold short. Based on an average daily volume of 79,218 shares, the short-interest ratio is currently 0.1 days.
Institutional Trading of CDT Equity
An institutional investor recently bought a new stake in CDT Equity stock. Great Lakes Advisors LLC acquired a new stake in CDT Equity Inc. (NASDAQ:CDT – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 18,631 shares of the company’s stock, valued at approximately $991,000. Great Lakes Advisors LLC owned 2.96% of CDT Equity at the end of the most recent reporting period. Hedge funds and other institutional investors own 3.29% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on CDT. Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a report on Wednesday, June 24th. Wall Street Zen upgraded CDT Equity from a “sell” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.
CDT Equity Price Performance
CDT stock remained flat at $1.69 during mid-day trading on Monday. The company’s stock had a trading volume of 112,890 shares, compared to its average volume of 286,282. The stock’s 50 day moving average is $4.06 and its 200 day moving average is $52.53. The company has a market capitalization of $1.33 million, a P/E ratio of -0.00 and a beta of 1.52. CDT Equity has a 12-month low of $1.60 and a 12-month high of $2,739.80.
CDT Equity (NASDAQ:CDT – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($8.71) earnings per share for the quarter.
CDT Equity Company Profile
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Featured Articles
- Five stocks we like better than CDT Equity
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
- AST SpaceMobile Is Down 54%—Can FCC Progress and BlueBirds Reverse the Slide?
- Don’t Miss These 3 Companies Delivering Strong Guidance Updates
Receive News & Ratings for CDT Equity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CDT Equity and related companies with MarketBeat.com's FREE daily email newsletter.
